Jason Bednar
Stock Analyst at Piper Sandler
(2.20)
# 2,811
Out of 5,124 analysts
190
Total ratings
40.69%
Success rate
-3.46%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $81.96 | +14.69% | 15 | Dec 5, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $194.07 | -2.10% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $142.67 | +20.56% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $79.24 | +23.67% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $17.64 | -3.63% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $88.14 | +23.67% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $156.15 | +28.08% | 32 | Oct 30, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $130.12 | +61.39% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $21.71 | -12.48% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $2.21 | +13.12% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.93 | +162.95% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $5.80 | -39.66% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.43 | +39.98% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $75.58 | +1.88% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.29 | +36.78% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $253.52 | +4.53% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.57 | +68.07% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.95 | +41.41% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.73 | +2,654.82% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $566.36 | -34.32% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $82.02 | +15.83% | 1 | Apr 19, 2023 |
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $81.96
Upside: +14.69%
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $194.07
Upside: -2.10%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $142.67
Upside: +20.56%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $79.24
Upside: +23.67%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $17.64
Upside: -3.63%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $88.14
Upside: +23.67%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $156.15
Upside: +28.08%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $130.12
Upside: +61.39%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $21.71
Upside: -12.48%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $2.21
Upside: +13.12%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.93
Upside: +162.95%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $5.80
Upside: -39.66%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.43
Upside: +39.98%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $75.58
Upside: +1.88%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.29
Upside: +36.78%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $253.52
Upside: +4.53%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.57
Upside: +68.07%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $4.95
Upside: +41.41%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.73
Upside: +2,654.82%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $566.36
Upside: -34.32%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $82.02
Upside: +15.83%